INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see ...
The government has established a concrete strategy to secure artificial intelligence (AI) technology, which has emerged as a game changer in the bio field. On the 30th, the Ministry of Science and ICT ...